Tri Locum Partners’s Mustang Bio MBIO Stock Holding History

Tri Locum Partners’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-44	Closed	-$13K	–	69
2022 Q4	$13K	Buy	+44	New	+$15K	0.01%	71

Other funds holding MBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SAG

Spotlight Asset Group Oakbrook Terrace, Illinois $143M AUM 20.66% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Tri Locum Partners's MBIO Position: Q1 2023 in Review

Tri Locum Partners sold out of Mustang Bio (MBIO) in Q1 2023, closing a stake of 44 shares — an estimated $13K sold.

Tri Locum Partners first reported a position in MBIO in Q4 2022 and held it in 1 quarter. The position peaked at $13K in Q4 2022. 48 funds tracked by Wall St. Rank hold MBIO as of Q1 2023.

Tri Locum Partners reported no remaining Mustang Bio position as of Q1 2023 after selling out during the quarter.
Tri Locum Partners sold 44 Mustang Bio shares in Q1 2023, an estimated $13K.
Tri Locum Partners first reported a position in Mustang Bio in Q4 2022 and held it in 1 quarter.
Tri Locum Partners's Mustang Bio position peaked at $13K in Q4 2022.
48 funds tracked by Wall St. Rank held Mustang Bio as of Q1 2023.

Based on Tri Locum Partners's 13F filing for Q1 2023, filed 15 May 2023.